Hepatitis c virus infection in chronic kidney disease

Journal of the American Society of Nephrology

Volumn 27, Issue 8, 2016, Pages 2238-2246

  Ladino, Marco ^a   Pedraza, Fernando ^a   Roth, David ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; SIMEPREVIR; SOFOSBUVIR; VELPATASVIR;

ANTIVIRAL THERAPY; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; REVIEW; COMPLICATION; HEPATITIS C, CHRONIC; RENAL INSUFFICIENCY, CHRONIC;

HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84992020588     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016010030     Document Type: Review

References (93)

1. Farci P: Choo QL, Kuo G,Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359-362]. J Hepatol 36: 582-585, 2002
2. Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D: Management of patients with hepatitis C infection and renal disease. World J Hepatol 7: 213-225, 2015
3. Kwo PY, Agrawal S: HCV/HIV coinfection: A new treatment paradigm. Gastroenterology 148: 1470-1471, 2015
4. Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK: Hepatitis C in hemodialysis patients. World J Hepatol 7: 548-558, 2015
5. Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331-338, 2003
6. Kidney Disease: Improving Global Outcomes (KDiGO): Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 109: S1-S99, 2008
7. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Wilson R: Membranoproliferative glomerulonephritis associated with hepatitisCvirus infection. NEnglJMed328: 465-470, 1993
8. Morales JM, KamarN, Rostaing L:Hepatitis C and renal disease: Epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol 176: 10-23, 2012
9. Pereira BJ, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C virus by organ transplantation. NEngl J Med 325: 454-460, 1991
10. Martin P, Fabrizi F: Hepatitis C virus and kidney disease. JHepatol 49: 613-624, 2008
11. Jang JY, Chung RT: Chronic hepatitis C. Gut Liver 5: 117-132, 2011
12. Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M: An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 32: 339-345, 2012
13. Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL: Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol 53: 967-972, 2015
14. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z: A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 22: 897-905, 2015
15. Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, Yu ML, Hwang SJ: Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 9: e100790, 2014
16. Chen YC, Chiou WY, Hung SK, Su YC, Hwang SJ: Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: A 6-year nationwide cohort study across Taiwan. BMC Nephrol 14: 187, 2013
17. Chen YC, Lin HY, Li CY, Lee MS, Su YC: A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 85: 1200-1207, 2014
18. Fabrizi F, Messa P, Martin P: Recent advances on hepatitis C virus in dialysis population. Kidney Blood Press Res 39: 260-271, 2014
19. Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, Kovesdy CP: Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61: 1495-1502, 2015
20. Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F: Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 25: 1237-1244, 1997
21. Scherzer R, Shlipak MG: Risk factors: Individual assessment of CKD risk in HIV-positive patients. Nat Rev Nephrol 11: 392-393, 2015
22. Klein MB, Rollet-Kurhajec KC, Moodie EE, Yaphe S, Tyndall M, Walmsley S, Gill J, Martel-Laferriere V, Cooper C; Canadian Co-infection Cohort Investigators: Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS 28: 1957-1965, 2014
23. Available at: http://emergency. cdc. gov/han/ han00386. asp. Accessed February 17, 2016
24. Bailey J, Balter P, Berns J, Butera E, Depner T, Douglas C, Duncan E, Edwards B, Favero M, Foreman J, Fried M, Gandi V, Glynn C, HakimR,HeardN, Lazaruz J, Levin N, Light P, Lindefield P, Masrshall C,Matyas B, Mazilli J, McCool B, Meisels I, Meyers C, Natov S, Nutter C, Pastan S, Peacock E, Polder J, Sharbaugh R, Shimojura G, Steinber J, Thomas-Hawkins C, Vas S,Walters D,Weber D, Wingard R,Wish J: ConsultantMeeting to Update Recommendations for the Prevention and Control of Bloodborne and Other Infections Among Chronic Hemodialysis Patients, 1999. Available at: http://www. cdc. gov/mmwr/preview/mmwrhtml/rr5005a1. htm. Accessed February 17, 2016
25. Ingsathit A, Kamanamool N, Thakkinstian A, Sumethkul V: Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: A systematic review and meta-analysis. Transplantation 95: 943-948, 2013
26. Fabrizi F, Dixit V, Messa P: Impact of hepatitis C on survival in dialysis patients: A link with cardiovascular mortality? J Viral Hepat 19: 601-607, 2012
27. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P: The impact of hepatitis C virus infection on survival in dialysis patients: Meta-analysis of observational studies. J Viral Hepat 14: 697-703, 2007
28. Fabrizi F, Ganeshan SV, Lunghi G, Messa P, Martin P: Antiviral therapy of hepatitis C in chronic kidney diseases: Meta-analysis of controlled clinical trials. J Viral Hepat 15: 600-606, 2008
29. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S: Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18: 1584-1593, 2007
30. Briggs JD: Causes of death after renal transplantation. Nephrol Dial Transplant 16: 1545-1549, 2001
31. Roth D, Gaynor JJ, Reddy KR, Ciancio G, Sageshima J, Kupin W, Guerra G, Chen L, Burke GW 3rd: Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 22: 1152-1160, 2011
32. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N: Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 18: 97-115, 2008
33. Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M: Hepatitis C virus infection and kidney transplantation in 2014: What's new? Am J Transplant 14: 2206-2220, 2014
34. Morales JM, Pascual-Capdevila J, Campistol JM, Fernandez-Zatarain G, Muñoz MA, Andres A, Praga M, Martinez MA, Usera G, Fuertes A, Oppenheimer F, Artal P, Darnell A, Rodicio JL: Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 63: 1634-1639, 1997
35. Cruzado JM, Carrera M, Torras J, Grinyó JM: Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 1: 171-178, 2001
36. RothD,Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, Carreno M, Esquenazi V, Miller J: De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 59: 1676-1682, 1995
37. Baid-Agrawal S, Farris AB 3rd, Pascual M, Mauiyyedi S, Farrell ML, Tolkoff-Rubin N, Collins AB, Frei U, Colvin RB: Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 80: 879-885, 2011
38. Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ: Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 138: 932-941, 2010
39. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann InternMed 133: 592-599, 2000
40. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G: Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant 5: 2433-2440, 2005
41. Delgado-Borrego A, Casson D, Schoenfeld D, SomsoukM, Terella A, Jordan SH, Bhan A, Baid S, Cosimi AB, Pascual M, Chung RT: Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 77: 703-710, 2004
42. Baid-Agrawal S, Frei U, Reinke P, Schindler R, Kopp MA, Martus P, Berg T, Juergensen JS, Anker SD, Doehner W: Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. AmJ Transplant 9: 2777-2784, 2009
43. Naing C, Mak JW, Wai N, Maung M: Diabetes and infections-hepatitis C: Is there type 2 diabetes excess in hepatitis C infection? Curr Diab Rep 13: 428-434, 2013
44. Fabrizi F, Martin P, Dixit V, Messa P: Metaanalysis of observational studies: Hepatitis C and survival after renal transplant. J Viral Hepat 21: 314-324, 2014
45. Morales JM, Bloom R, Roth D: Kidney transplantation in the patient with hepatitis C virus infection. Contrib Nephrol 176: 77-86, 2012
46. Sezer S, Ozdemir FN, Akcay A, Arat Z, Boyacioglu S, Haberal M: Renal transplantation offers a better survival in HCVinfected ESRD patients. Clin Transplant 18: 619-623, 2004
47. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ: The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 29: 608-614, 1997
48. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS; The New England Organ Bank Hepatitis C Study Group: Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 53: 1374-1381, 1998
49. Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR: Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 5: 139-144, 2005
50. Heim MH: 25 years of interferon-based treatment of chronic hepatitis C: An epoch coming to an end. Nat Rev Immunol 13: 535-542, 2013
51. Maruyama A, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T: A review of directacting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease [published online ahead of print October 19, 2015]. Nephrol Dial Transplant
52. Gilead Sciences, Inc. : Sovaldi 400 mg Tablets (Sofosbuvir) Product Monograph, 2014. Available at: http://www. gilead. ca/pdf/ca/ sovaldi-pm-english. pdf. Accessed November 15, 2015
53. Kirby BJ, Symonds WT, Kearney BP, Mathias AA: Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitisC virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 54: 677-690, 2015
54. Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L, Roth D, Schiff E, O'Brien C, Martin P: Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol 63: 763-765, 2015
55. Sabucedo A, Antoine M, Jorge D, Andreu A, Pedraza F, HernandezM, Jeffers L, LadinoM: Sofosbuvir use in patients with Hepatitis C virus infection and severe chronic kidney disease [Abstract]. J Am Soc Nephrol 26: 663A, 2015
56. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault N: HCV-TARGET: Safety and efficacy of sofosbuvir-containing regimens in HCV infected patients with impaired renal function [published online ahead of print February 29, 2016]. Liver Int doi: 10. 1111/liv. 13102
57. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America: HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Unique Patient Populations: Patients with Renal Impairment, 2015. Available at: http://www. hcvguidelines. org/ full-report/unique-patient-populationspatients-renal-impairment. AccessedNovember 15, 2015
58. Janssen, Inc. : Galexos (Simeprevir) Product Monograph, 2015. Available at: http://www. janssen. ca/product/575. Accessed November 15, 2015
59. Gilead Sciences, Inc. : HARVONI (Ledipasvir/ Sofosbuvir 90 mg/400 mg) Product Monograph, 2014. Available at: http://www. gilead. ca/pdf/ca/harvoni-pm-french. pdf. Accessed November 15, 2015
60. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889-1898, 2014
61. AbbVie Inc. : Viekira Pak [Package Insert]. Available at: http://www. viekirahcp. com/ dosing/mechanism-of-action/, http://www. viekirahcp. com/dosing/regimen/. Accessed November 15, 2015
62. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein D, Podsadecki T, Cohen D, Shulman NS: Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV G1 infection in patients with severe renal impairment or endstage renal disease: The RUBY?1 study [Abstract]. J Hepatol 62: S257, 2015
63. Bristol-Myers Squibb Company: Daklinza [Package Insert]. Available at: http://www. daklinzahcp. bmscustomerconnect. com. Accessed November 15, 2015
64. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, BennettM, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team: All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61: 1127-1135, 2015
65. Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, Marbury TC, Alcorn H, Bertz R, Bifano M: Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther 20: 535-543, 2015
66. Yeh W, Caro L, Guo Z, Hwa-Ping F, Davis H, Kozisek M, Stypinski D, Fen C, Mitchell C, Gillespie A, Ichhpurani N, Marshall W, Lasseter K, Marbury T, Butterton J: Pharmacokinetics of co-administered HCV protease inhibitor grazoprevir (MK-5172) and NS5A elbasivr (MK-8742) in volunteers with endstage renal disease on hemodialysis or severe renal impairment not on hemodialysis [Abstract]. J Hepatol 60[Suppl 4]: 1940, 2014
67. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr., Martin P, Pol S, Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitisCvirus genotype 1 infection and stage 4-5 chronic kidney disease (theC-SURFER study): A combination phase 3 study. Lancet 386: 1537-1545, 2015
68. Chan HL, Li PK: Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD. Nat Rev Nephrol 12: 5-6, 2016
69. Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-TorresM: A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patientswith genotype 1-4 hepatitis C virus. J Viral Hepat 22: 1011-1019, 2015
70. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators: Sofosbuvir and velpatasvir for HCVgenotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373: 2599-2607, 2015
71. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, ShiffmanML, Cooper C, TownerWJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators: Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. NEngl J Med 373: 2608-2617, 2015
72. Castera L: Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142: 1293-1302. e4, 2012
73. Sawinski D, Bloom RD: Novel Hepatitis C treatments and the impact on kidney transplantation. Transplantation 99: 2458-2466, 2015
74. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD: Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant 8: 2243-2251, 2008
75. Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL: Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant 10: 1238-1246, 2010
76. Reese PP, Abt PL, Blumberg EA, Goldberg DS: Transplanting hepatitis C-positive kidneys. N Engl J Med 373: 303-305, 2015
77. Abbott KC, Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Cruess DF, Peters TG: Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 14: 2908-2918, 2003
78. Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A: Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg 5: 294-300, 1999
79. Althaf MM, Abdelsalam MS, Rashwan M, Nadri Q: Acute hepatitis C infection in a renal transplant recipient: Primacy of the liver or kidney? BMJ Case Rep 2014: bcr2014203530, 2014
80. Issa D, Eghtesad B, Zein NN, Yerian L, Cruise M, Alkhouri N, Adams R, Hanouneh IA: Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation. Int J Organ Transplant Med 7: 38-45, 2016
81. Saab S, Jimenez M, Bau S, Goo T, Zhao D, Durazo F, Han S, El KabanyM, Kaldas F, Tong MJ, Busuttil RW: Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: A matched analysis. Clin Transplant 29: 813-819, 2015
82. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, PrietoM, Fontana RJ, Baumert TF, Coilly A, Londoño MC, Habersetzer F: Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61: 1485-1494, 2015
83. Delabaudière C, Lavayssière L, Dörr G, Muscari F, Danjoux M, Sallusto F, Peron JM, Bureau C, Rostaing L, Izopet J, Kamar N: Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transpl Int 28: 255-258, 2015
84. Coilly A, Samuel D: Pros and cons: Usage of organs from donors infected with hepatitis C virus-Revision in the direct-acting antiviral era. J Hepatol 64: 226-231, 2016
85. Morales JM, Fabrizi F: Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol 11: 172-182, 2015
86. Ozgür O, Boyacioglu S, Telatar H, Haberal M: Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. NephrolDial Transplant 10: 2104-2106, 1995
87. Rostaing L, Izopet J, Baron E, DuffautM, Puel J,Durand D: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59: 1426-1431, 1995
88. Rosen HR: Clinical practice. Chronic hepatitis C infection. N Engl J Med 364: 2429-2438, 2011
89. Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD: Successful treatment of Hepatitis C in renal transplant recipients with direct-acting antiviral agents [published online ahead of print November 25, 2015]. Am J Transplant doi: 10. 1111/ajt. 13620
90. Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, Esposito L, Del Bello A, Métivier S, Barange K, Izopet J, Alric L: Efficacy and safety of sofosbuvirbased antiviral therapy to treat hepatitis C virus infection after kidney transplantation [published online ahead of print November 20, 2015]. Am J Transplant doi: 10. 1111/ ajt. 13518
91. Pipili C, Cholongitas E: Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients. World J Gastrointest Pharmacol Ther 6: 105-110, 2015
92. Wolffenbüttel L, Poli DD, Manfro RC, Gonçalves LF: Cyclosporine pharmacokinetics in anti-HCV+ patients. Clin Transplant 18: 654-660, 2004
93. Oo YH, Dudley T, Nightingale P, Haydon G, Mutimer D: Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl 14: 81-87, 2008